Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision Medicine.

Bhagwat SV, McMillen WT, Cai S, Zhao B, Whitesell M, Shen W, Kindler L, Flack RS, Wu W, Anderson B, Zhai Y, Yuan XJ, Pogue M, Van Horn RD, Rao X, McCann D, Dropsey AJ, Manro J, Walgren J, Yuen E, Rodriguez MJ, Plowman GD, Tiu RV, Joseph S, Peng SB.

Mol Cancer Ther. 2019 Nov 19. pii: molcanther.0183.2019. doi: 10.1158/1535-7163.MCT-19-0183. [Epub ahead of print]

PMID:
31744895
2.

Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy.

Du J, Yan L, Torres R, Gong X, Bian H, Marugán C, Boehnke K, Baquero C, Hui YH, Chapman SC, Yang Y, Zeng Y, Bogner SM, Foreman RT, Capen A, Donoho GP, Van Horn RD, Barnard DS, Dempsey JA, Beckmann RP, Marshall MS, Chio LC, Qian Y, Webster YW, Aggarwal A, Chu S, Bhattachar S, Stancato LF, Dowless MS, Iversen PW, Manro JR, Walgren JL, Halstead BW, Dieter MZ, Martinez R, Bhagwat SV, Kreklau EL, Lallena MJ, Ye XS, Patel BKR, Reinhard C, Plowman GD, Barda DA, Henry JR, Buchanan SG, Campbell RM.

Mol Cancer Ther. 2019 Dec;18(12):2207-2219. doi: 10.1158/1535-7163.MCT-18-0529. Epub 2019 Sep 17.

PMID:
31530649
3.

Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene.

Gong X, Du J, Parsons SH, Merzoug FF, Webster Y, Iversen PW, Chio LC, Van Horn RD, Lin X, Blosser W, Han B, Jin S, Yao S, Bian H, Ficklin C, Fan L, Kapoor A, Antonysamy S, Mc Nulty AM, Froning K, Manglicmot D, Pustilnik A, Weichert K, Wasserman SR, Dowless M, Marugán C, Baquero C, Lallena MJ, Eastman SW, Hui YH, Dieter MZ, Doman T, Chu S, Qian HR, Ye XS, Barda DA, Plowman GD, Reinhard C, Campbell RM, Henry JR, Buchanan SG.

Cancer Discov. 2019 Feb;9(2):248-263. doi: 10.1158/2159-8290.CD-18-0469. Epub 2018 Oct 29.

PMID:
30373917
4.

Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor.

Wijeratne A, Xiao J, Reutter C, Furness KW, Leon R, Zia-Ebrahimi M, Cavitt RN, Strelow JM, Van Horn RD, Peng SB, Barda DA, Engler TA, Chalmers MJ.

ACS Med Chem Lett. 2018 May 21;9(6):557-562. doi: 10.1021/acsmedchemlett.8b00110. eCollection 2018 Jun 14.

5.

Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587.

Peng SB, Van Horn RD, Yin T, Brown RM, Roell WC, Obungu VH, Ruegg C, Wroblewski VJ, Raddad E, Stille JR.

Oncotarget. 2017 Oct 10;8(55):94619-94634. doi: 10.18632/oncotarget.21816. eCollection 2017 Nov 7.

6.

RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.

Chen SH, Gong X, Zhang Y, Van Horn RD, Yin T, Huber L, Burke TF, Manro J, Iversen PW, Wu W, Bhagwat SV, Beckmann RP, Tiu RV, Buchanan SG, Peng SB.

Oncogene. 2018 Feb 8;37(6):821-832. doi: 10.1038/onc.2017.384. Epub 2017 Oct 23.

PMID:
29059158
7.

Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.

Yao YM, Donoho GP, Iversen PW, Zhang Y, Van Horn RD, Forest A, Novosiadly RD, Webster YW, Ebert P, Bray S, Ting JC, Aggarwal A, Henry JR, Tiu RV, Plowman GD, Peng SB.

Clin Cancer Res. 2017 Sep 15;23(18):5547-5560. doi: 10.1158/1078-0432.CCR-16-3250. Epub 2017 Jun 13.

8.

Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.

Chen SH, Zhang Y, Van Horn RD, Yin T, Buchanan S, Yadav V, Mochalkin I, Wong SS, Yue YG, Huber L, Conti I, Henry JR, Starling JJ, Plowman GD, Peng SB.

Cancer Discov. 2016 Mar;6(3):300-15. doi: 10.1158/2159-8290.CD-15-0896. Epub 2016 Jan 5.

9.

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.

Peng SB, Henry JR, Kaufman MD, Lu WP, Smith BD, Vogeti S, Rutkoski TJ, Wise S, Chun L, Zhang Y, Van Horn RD, Yin T, Zhang X, Yadav V, Chen SH, Gong X, Ma X, Webster Y, Buchanan S, Mochalkin I, Huber L, Kays L, Donoho GP, Walgren J, McCann D, Patel P, Conti I, Plowman GD, Starling JJ, Flynn DL.

Cancer Cell. 2015 Sep 14;28(3):384-98. doi: 10.1016/j.ccell.2015.08.002. Epub 2015 Sep 3.

10.

A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models.

Ye XS, Fan L, Van Horn RD, Nakai R, Ohta Y, Akinaga S, Murakata C, Yamashita Y, Yin T, Credille KM, Donoho GP, Merzoug FF, Li H, Aggarwal A, Blanchard K, Westin EH.

Mol Cancer Ther. 2015 Nov;14(11):2463-72. doi: 10.1158/1535-7163.MCT-15-0241. Epub 2015 Aug 24.

11.

The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.

Yadav V, Burke TF, Huber L, Van Horn RD, Zhang Y, Buchanan SG, Chan EM, Starling JJ, Beckmann RP, Peng SB.

Mol Cancer Ther. 2014 Oct;13(10):2253-63. doi: 10.1158/1535-7163.MCT-14-0257. Epub 2014 Aug 13.

12.

p38 mitogen-activated protein kinase promotes cell survival in response to DNA damage but is not required for the G(2) DNA damage checkpoint in human cancer cells.

Phong MS, Van Horn RD, Li S, Tucker-Kellogg G, Surana U, Ye XS.

Mol Cell Biol. 2010 Aug;30(15):3816-26. doi: 10.1128/MCB.00949-09. Epub 2010 Jun 1.

13.

Cdk1 activity is required for mitotic activation of aurora A during G2/M transition of human cells.

Van Horn RD, Chu S, Fan L, Yin T, Du J, Beckmann R, Mader M, Zhu G, Toth J, Blanchard K, Ye XS.

J Biol Chem. 2010 Jul 9;285(28):21849-57. doi: 10.1074/jbc.M110.141010. Epub 2010 May 5.

14.

Th2 cytokines IL-4 and IL-13 downregulate paxillin expression in bronchial airway epithelial cells.

Ramirez-Icaza G, Mohammed KA, Nasreen N, Van Horn RD, Hardwick JA, Sanders KL, Tian J, Ramirez-Icaza C, Johnson MT, Antony VB.

J Clin Immunol. 2004 Jul;24(4):426-34.

PMID:
15163899
15.

Pleural mesothelial cell (PMC) defense mechanisms against malignancy.

Nasreen N, Mohammed KA, Sanders K, Hardwick J, Van Horn RD, Sriram PS, Ramirez-Icaza C, Hage C, Antony VB.

Oncol Res. 2003;14(3):155-61.

PMID:
14760864
16.

Mycobacteria induces pleural mesothelial permeability by down-regulating beta-catenin expression.

Mohammed KA, Nasreen N, Hardwick J, Van Horn RD, Sanders KL, Antony VB.

Lung. 2003;181(2):57-66.

PMID:
12953144
17.

Defensive role of pleural mesothelial cell sialomucins in tumor metastasis.

Sharma RK, Mohammed KA, Nasreen N, Hardwick J, Van Horn RD, Ramirez-Icaza C, Antony VB.

Chest. 2003 Aug;124(2):682-7.

PMID:
12907560
18.

Pleural mesothelial cells modulate polymorphonuclear leukocyte apoptosis in empyema.

Nasreen N, Mohammed KA, Sanders KL, Hardwick J, Van Horn RD, Sharma RK, Kilani M, Antony VB.

J Clin Immunol. 2003 Jan;23(1):1-10.

PMID:
12645855
19.

Low molecular weight hyaluronan induces malignant mesothelioma cell (MMC) proliferation and haptotaxis: role of CD44 receptor in MMC proliferation and haptotaxis.

Nasreen N, Mohammed KA, Hardwick J, Van Horn RD, Sanders K, Kathuria H, Loghmani F, Antony VB.

Oncol Res. 2002;13(2):71-8.

PMID:
12392154
20.

Induction of MCP-1 expression in airway epithelial cells: role of CCR2 receptor in airway epithelial injury.

Lundien MC, Mohammed KA, Nasreen N, Tepper RS, Hardwick JA, Sanders KL, Van Horn RD, Antony VB.

J Clin Immunol. 2002 May;22(3):144-52.

PMID:
12078856
21.

Inflammatory cytokines mediate C-C (monocyte chemotactic protein 1) and C-X-C (interleukin 8) chemokine expression in human pleural fibroblasts.

Loghmani F, Mohammed KA, Nasreen N, Van Horn RD, Hardwick JA, Sanders KL, Antony VB.

Inflammation. 2002 Apr;26(2):73-82.

PMID:
11989790
22.

Polar production of interleukin-8 by mesothelial cells promotes the transmesothelial migration of neutrophils: role of intercellular adhesion molecule-1.

Nasreen N, Mohammed KA, Hardwick J, Van Horn RD, Sanders KL, Doerschuk CM, Hott JW, Antony VB.

J Infect Dis. 2001 Jun 1;183(11):1638-45. Epub 2001 Apr 27.

PMID:
11343213

Supplemental Content

Loading ...
Support Center